Evidence map›Paper›PMID 39570967›Full record

ArticlePloS one2024

Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder.

Raymond R Balise, Mei-Chen Hu, Anna R Calderon, Gabriel J Odom, Laura Brandt, Sean X Luo, Daniel J Feaster

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raymond R BaliseDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States of America.ORCID 0000-0002-9856-5901
Mei-Chen HuDepartment of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, United States of America.
Anna R CalderonDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States of America.ORCID 0000-0002-0139-3841
Gabriel J OdomDepartment of Biostatistics, Stempel College of Public Health, Florida International University, Miami, Florida, United States of America.ORCID 0000-0003-1341-4555
Laura BrandtDepartment of Psychology, City College of New York, New York, New York, United States of America.
Sean X LuoDepartment of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, United States of America.ORCID 0000-0002-6289-9168
Daniel J FeasterDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States of America.ORCID 0000-0002-6172-7460

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
NIDA NIH HHS T32 DA037801NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013720
6 · The paper itself

Abstract

Several large-scale, pragmatic clinical trials on opioid use disorder (OUD) have been completed in the National Drug Abuse Treatment Clinical Trials Network (CTN). However, the resulting data have not been harmonized between the studies to compare the patient characteristics. This paper provides lessons learned from a large-scale harmonization process that are critical for all biomedical researchers collecting new data and those tasked with combining datasets. We harmonized data from multiple domains from CTN-0027 (N = 1269), which compared methadone and buprenorphine at federally licensed methadone treatment programs; CTN-0030 (N = 653), which recruited patients who used predominantly prescription opioids and were treated with buprenorphine; and CTN-0051 (N = 570), which compared buprenorphine and extended-release naltrexone (XR-NTX) and recruited from inpatient treatment facilities. Patient-level data were harmonized and a total of 23 database tables, with meticulous documentation, covering more than 110 variables, along with three tables with "meta-data" about the study design and treatment arms, were created. Domains included: social and demographic characteristics, medical and psychiatric history, self-reported drug use details and urine drug screening results, withdrawal, and treatment drug details. Here, we summarize the numerous issues with the organization and fidelity of the publicly available data which were noted and resolved, and present results on patient characteristics across the three trials and the harmonized domains, respectively. A systematic harmonization of OUD clinical trial data can be accomplished, despite heterogeneous data coding and classification procedures, by standardizing commonly assessed characteristics. Similar methods, embracing database normalization and/or "tidy" data, should be used for future datasets in other substance use disorder clinical trials.

Indexed as

BuprenorphineNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersAdultAnalgesics, OpioidClinical Trials as TopicDatabases, FactualFemaleHumansMaleMethadoneMiddle AgedAnalgesics, OpioidBuprenorphineMethadoneNaltrexone

Identifiers

PMID39570967
PMCPMC11581333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.